Figure 4.
Therapeutic Vaccination with SMARRT.Ancer Inhibits Tumor Growth and Enhances Survival
Mice were implanted with 3 × 105 CT26 cells s.c. at day 0. SMARRT was injected i.m. on days 3 and 17. Tumor growth (A) and overall survival (B) were measured (n = 18/group). In a separate study, mice (n = 6/group) were injected with CT26 and SMARRT constructs as described above; additionally, some groups received anti-PD-1 blocking mAbs on days 8, 11, 15, and 18. (C) Shows tumor growth until day 23. Tumors were excised on day 23 and T cells were analyzed by flow cytometry for cytokine production following ex vivo peptide re-stimulation. (D) Shows CD8 T cells and (E) shows CD4 T cells. Tumor growth curves show median tumor volume, and statistical testing was done with two-way ANOVA. Survival curve statistical testing was done using log-rank (Mantel Cox) test. Bar graphs show mean with standard deviation. ∗p < 0.05; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.